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Abstract
Objectives To examine how much of the observed rapid decrease in
mortality from coronary heart disease in Poland after the political, social,
and economic transformation in the early 1990s could be explained by
the use of medical and surgical treatments and how much by changes
in cardiovascular risk factors.
Design A modelling study.
Setting Sources of data included controlled trials and meta-analyses,
national surveys, and official statistics.
Participants Population of adults aged 25-74 in Poland in 1991-2005.
Main outcome measures Number of deaths prevented or postponed
in 2005 attributable to specific treatments for coronary heart disease
and changes in risk factors. A previously validated epidemiological model
for coronary heart disease was used to combine and analyse data on
the uptake and effectiveness of specific cardiac treatments and changes
in risk factors. The observed fall in deaths from coronary heart disease
from 1991 to 2005 was then partitioned among specific treatments and
risk factor changes.
Results From 1991 to 2005, the death rate from coronary heart disease
in Poland halved, resulting in 26 200 fewer coronary deaths in 2005 in
people aged 25-74. About 37% (minimum estimate 13%, maximum
estimate 77%) of this decrease was attributable to treatments, including
treatments for heart failure (12%), initial treatments for acute coronary
syndrome (9%), secondary prevention treatments after myocardial
infarction or revascularisation (7%), chronic angina treatments (3%),
and other treatments (6%). About 54% of the fall was attributed to
changes in risk factors (minimum estimate 41%, maximum estimate
65%), mainly reductions in total cholesterol concentration (39%) and an
increase in leisuretime physical activity (10%); however, these were
partially offset by increases in body mass index (−4%) and prevalence
of diabetes (−2%). Blood pressure fell in women, explaining about 29%
of their decrease in mortality, but rose in men generating a negative
influence (−8%). About 15% of the observed decrease in mortality was
attributable to reduced smoking in men but was negligible in women.
Conclusions Over half of the recent fall in mortality from coronary heart
disease in Poland can be attributed to reductions in major risk factors
and about one third to evidence based medical treatments.
Introduction
Cardiovascular deaths in Poland increased steadily through the
1970s and 1980s. Indeed, this unfavourable trend continued to
theendofthecommunistera.Dramaticsocioeconomicchanges
then occurred during the transition to a market economy. There
were sudden sharp falls in mortality from 1991 onwards,
1 one
of the fastest declines in the world. The improvements in life
expectancy were mainly attributable to decreases in
cardiovascular mortality.
1 Several central and eastern countries
in Europe experienced equally dramatic political and
socioeconomic changes in the 1990s, including the Czech
Republic, Hungary, and Romania (fig 1⇓.
2
Some aspects of this phenomenon in Poland have been
previously analysed, particularly the role of dietary changes.
4 5
When subsidies for animal fats during the socialist era
disappeared, consumption fell dramatically, while the intakes
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Research
RESEARCHofpolyunsaturatedfats,fruits,andvegetablesallincreasedafter
the introduction of a market economy.
The potential contribution of treatments and other risk factors
remains unclear. For instance, the prevalence of smoking in
men also fell considerably during that period.
5 6 Changes in
other cardiovascular risk factors might also have played an
important role in the observed decline in mortality.
Improvements in evidence based treatments for established
coronary disease also became widely used in recent decades in
Poland. This included treatments for hypercholesterolaemia,
hypertension, coronary heart disease, and heart failure, as well
ascoronarybypasssurgery,coronaryangioplasty,andstenting.
These changes might be important contributors to the observed
reductions in mortality.
The contribution of changes in levels of risk factors and the
uptake of evidence based treatments to the change in mortality
rates from coronary heart disease has been well studied in
Western countries, where the decline in mortality started much
earlier
7 8 9, but has not been analysed in central European
populations, particularly in Poland, the largest.
We investigated the contribution of changes in risk factors and
evidencebasedtreatmentstotherecentfallincoronarymortality
observed in Poland since 1991. Such an analysis is potentially
important, both for understanding past trends and also for
planning future strategies.
Methods
To explain the changes in cardiovascular mortality in Poland
between 1991 and 2005 we used the IMPACT coronary heart
disease mortality model. This has been previously validated in
the United Kingdom, Italy, Sweden, Canada, and the United
States.
7-11Descriptionsofthemodelhavealreadybeenpublished
elsewhereandaredetailedinthetechnicalappendixonbmj.com.
In brief, the model aims to be comprehensive, incorporating all
major cardiovascular risk factors, including blood pressure,
cholesterol concentration, diabetes, smoking, overweight, and
obesity, plus all usual treatments for coronary heart disease and
heart failure.
Wesystematicallyidentifiedandcriticallyreviewedallavailable
PolishdatasourcesasinputsinthePolishIMPACTmodel.The
analysis was confined to adults aged 25-74. Mortality and
demographic data were taken from routine national statistics.
Numbersofrelevantpatientsandtreatmentswereobtainedfrom
crosssectionalnationalandlocalstudies,representativesurveys
for the country (WOBASZ,
12 NATPOL,
13 14 Pol-MONICA
15),
national registries (coronary artery bypass surgery (CABG)
registry,
16 acute coronary syndromes registry
17), and hospital
discharge databases. We also elicited expert opinions when
objective data were deficient. Data quantifying changes in the
prevalence of cardiovascular risk factors were taken from
nationalrepresentativesurveys(NATPOL,WOBASZ,)aswell
as from the best regional and local epidemiological studies
(Pol-MONICA and CINDI WHO
18).
Trends in mortality from coronary heart
disease in Poland 1991-2005
We obtained age and sex specific mortality rates for coronary
heart disease from the Central Statistical Office. Substantial
changes in the coding of causes of death in Poland were
introducedin1997.Assessmentofthetruedeclineinthenumber
of deaths from coronary heart disease in Poland for 1999-2005
thereforerequireddetailedanalysisandadjustmentoftheofficial
data derived from the Central Statistical Office covering the
period1991-6.Adetaileddescriptionofthemethodssupporting
this correction has been described elsewhere.
19
Estimating the number of deaths prevented
or postponed
Wesubtractedthenumberofdeathsfromcoronaryheartdisease
expectedin2005,ifthe1991mortalityrateshadpersisted,from
the number of deaths actually observed in 2005 to produce the
fall in mortality that the model needed to explain. We then
estimated the proportions of that total number of deaths
prevented or postponed that could be attributed to the use of
treatments and to changes in cardiovascular risk factors.
Benefits from treatment
Data on the clinical effectiveness of each intervention and
treatment were based on the most recent meta-analyses and
large randomised clinical trials (table 1⇓ and see appendix on
bmj.com).
We calculated the number of deaths prevented or postponed as
aresultofeachindividualinterventionineachgroupofpatients
withcoronaryheartdiseasein2005(table1)bymultiplyingthe
number of patients in each diagnostic group by their baseline
case fatality rate over one year by the proportion of these
patients receiving a specific treatment and by the relative
reductioninoneyearcasefatalitybytheadministeredtreatment.
For example, in Poland in 2005, about 12 230 men aged 55-64
were admitted to hospital with acute myocardial infarction.
Theirexpectedagespecificcasefatalityrateatoneyearwithout
treatment was about 5.4%. From registry data
20 96% of them
weregivenaspirinorotherantiplateletdrugs;interventionswith
anexpectedreductioninmortalityof15%.Thenumberofdeaths
prevented or postponed for at least a year by the use of aspirin
among men aged 55-64 was then calculated as:
12 230×0.054×0.96×0.15=95 fewer deaths.
We then repeated this process for men and women in each age
group, each patient group, and for each treatment. Some
adjustments were made to these basic analyses. Many evidence
basedtreatmentswerenotusedinPolandin1991(suchasstatins
orprimaryangioplastyinacutemyocardialinfarction).Insome
cases, however, the use of some drugs or procedures in 1991
was not negligible (for instance, antihypertensive treatment or
aspirin in acute myocardial infarction). In such cases, to obtain
the net benefit, we calculated the number of deaths prevented
or postponed as a result of the treatment as used in 1991 and
subtracted this from the number calculated for 2005.
Compliance (adherence, the proportion of treated patients
actually taking effective levels of drugs) was assumed to be
100% among patients in hospital, 70% among symptomatic
patients in the community, and 50% among asymptomatic
patients in the community.
21 To avoid double counting of
patients, we identified potential overlaps between different
groups of patients. Assumptions concerning these overlaps are
presented in the appendix on bmj.com. To quantify the relative
reduction in case fatality rate for individual patients receiving
multiple treatments, we used the conventional Mant and Hicks
cumulative relative benefit approach
22:
relative benefit=1−[(1−relative reduction in case fatality rate
for treatment A)×(1−relative reduction in case fatality rate for
treatment B)×. . . ×(1−relative reduction in case fatality rate for
treatment N)].
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RESEARCHChanges in risk factors and benefits on
mortality
Regression approach
We used published regression coefficients to calculate the
number of deaths prevented or postponed as a result of changes
in systolic blood pressure, mean cholesterol concentration, and
body mass index (BMI). The number was the product of the
number of deaths from coronary heart disease observed in the
baseline year (1991), the change in level of the risk factor, and
thecoefficientquantifyingthechangeinmortalityfromcoronary
heart disease per unit of absolute change in that risk factor.
Forexample,therewere2534deathsfromcoronaryheartdisease
amongwomenaged55-64in1991,thebaseyear.Meansystolic
blood pressure in this group decreased by 5.4 mm Hg between
1991and2005.Thelargestmeta-analysisshowsanageandsex
specific reduction in mortality of 50% for every 20 mm Hg
reduction in systolic blood pressure, generating a logarithmic
coefficient of −0.035.
23 The number of deaths prevented or
postponed was then estimated as:
[deaths in
1991]×(1−exp(coefficient×change)=2534×(1−exp(−0.035×5.4))=436
fewer deaths.
Population attributable risk approach
We used a population attributable risk fraction approach to
assess the effect of changes in the prevalence of smoking,
diabetes, and physical inactivity, using the standard formula
((P×(RR−1))/(1+P×(RR−1))
where P=prevalence of the risk factor and RR=the relative risk
of mortality from coronary heart disease associated with that
risk factor.
To assess the decline in mortality from coronary heart disease,
wemultipliedthenumberofdeathsfromcoronaryheartdisease
in1991(thebaseyear)bythedifferencebetweenthepopulation
attributable risk fraction in 1991 and that in 2005.
We assumed that there was no further synergy between the
treatment and risk factor sections of the model or between the
majorriskfactorsbecausetheregressioncoefficientsandrelative
risksforeachriskfactorwereeachindependent,beingobtained
from multivariate analyses. Deaths prevented or postponed as
a result of changes in risk factors were then systematically
quantified for each group of patients. Lag times between rates
of change in risk factors and rates of change in events were not
modelled. We assumed, as in other countries, that any time lag
would be relatively unimportant over a period of 15 years
(1991-2005).
24
Model validation: comparison of estimated v
observed changes in mortality
The model produces estimates of the total number of deaths
fromcoronaryheartdiseasepreventedorpostponedattributable
to each treatment and to changes in each specific risk factor.
These estimates were then summed and compared with the
observed changes in mortality for men and women in each
specific age group. Any shortfall in the overall estimate from
the model was then presumed to be attributable to inaccuracies
inourmethods.Inparticular,thesecanbebiasedinputdataand
insufficientaccountingfortimelag.Othercausesofthisshortfall
canbeotherunmeasuredriskfactors,suchaspsychosocialones
or physical activity in work (we accounted only for leisuretime
physical activity).
Sensitivity analyses
Alltheaboveassumptionsweretestedinamulti-waysensitivity
analysiswiththeanalysisofextremesmethod.
25Foreachmodel
parameter, we assigned a lower and upper value using 95%
confidence intervals where available or ±20% values (for
numbersofpatients,uptakeoftreatment,andcompliance).More
detailed information concerning the methods is provided in the
technical appendix on bmj.com.
Results
Thedeclineinmortalityratesfromcoronaryheartdiseasesince
1991resultedin26200fewerdeathsfromcoronaryheartdisease
in 2005. The model explained about 91% (23 715) of this
decrease.
About 37% of the decrease was attributable to treatments
(minimum estimate 13%, maximum estimate 77%) and about
54% was attributable to changes in risk factors (minimum
estimate 41%, maximum estimate 65%). There was generally
good agreement between the estimated and observed number
of deaths across all sex and age groups. In middle aged men,
however,thenumberofpredicteddeathspreventedorpostponed
was underestimated (fig 2⇓).
Changes in risk factors
About 14 070 of the deaths from coronary heart disease
prevented or postponed (54%) were attributable to changes in
risk factors. Most (41% of the fall in men and 33% in women)
were attributable to large decreases in mean cholesterol
concentration (declining by 0.4 mmol/L). This fall in deaths
concerns changes in mean cholesterol concentration related to
diet only and was calculated by subtraction of drug related
effects from total effect of mean cholesterol change.
The effects of changes in smoking and mean blood pressure in
men and women were more complex. In men, the prevalence
of smoking decreased by 15.7%, explaining about 15% of their
fall in mortality. There was little change in the prevalence of
smoking in women, which therefore had virtually no effect on
mortality from coronary heart disease. Mean systolic blood
pressurefellby2.7mmHginmenandby5.2mmHginwomen.
After subtraction of the effects of treatments for hypertension,
thesefallsinbloodpressureexplainedabout29%ofthedecrease
in mortality in women and 8% of the increase in deaths in men
(table 2⇓). Increased leisuretime physical activity explained
about 10% of the decrease in deaths.
Thesegainswerepartiallyoffsetbyabout1810additionaldeaths
attributable to increases in BMI (−4% and −5% for men and
women, respectively) and prevalence of diabetes (−1% and
−8%, respectively) (table 2⇓).
Medical and surgical treatments
Table 1 shows the estimated numbers of deaths from coronary
heart disease prevented or postponed by medical and surgical
treatment in 2005⇓. All treatments accounted for about 9640
fewer deaths, representing about 37% of the decrease in
mortality.Thelargestreductionscamefromtreatmentsforheart
failureinhospitalandinthecommunity,whichresultedinabout
3100 fewer deaths in 2005 (12% of the observed reduction in
mortality). Initial treatments for acute myocardial infarction or
unstable angina generated about 2450 fewer deaths (9% of the
observedfall).Secondarypreventiontreatmentsaftermyocardial
infarctionorrevascularisationexplainedabout1930(7%)fewer
deaths, followed by treatments for chronic angina (710, 3%) or
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in primary prevention (880, 3%).
Sensitivity analysis
Under the assumptions of the sensitivity analysis, the relative
contributions of changes in specific risk factors and treatment
effectsremainedsimilar.Theextrememinimumandmaximum
numbersofcoronaryheartdiseasedeathspreventedorpostponed
were 14 050 (54% of the observed fall in mortality) and 36 840
(141%).
Discussion
Key findings
InPolandin2005therewere26200fewercoronarydeathsthan
in 1991, about 54% being attributable to beneficial changes in
risk factors and 37% to the increased use of evidence based
treatments. The major contributors to the fall in mortality were
large changes in total cholesterol concentration related to diet,
plus beneficial trends in systolic blood pressure in women and
decreased smoking in men. Physical activity also contributed.
Worryingly, adverse trends negated some of these benefits,
specifically obesity, diabetes, and blood pressure in men and
smoking in women.
The most important treatment contributions came from
treatments for heart failure, angina, and secondary prevention.
Cardiovascular diseases, however, still remain a major cause
of mortality and morbidity in Poland. It is therefore crucial to
better understand the drivers of these favourable and adverse
trends to continue or even to accelerate the pace of decline by
using well planned and cost effective interventions.
Neighbouring countries
This study implemented the first IMPACT model in central
Europe. These results should be cautiously generalisable to the
many neighbouring former communist countries that
experienced similar trends in mortality after their political
transformations: the Czech Republic, Slovakia, Hungary, East
Germany, and Romania. In contrast, trends in mortality
fluctuated in some other former communist countries, which
experiencedmorecomplicatedpatternsofchangesafterthefall
ofcommunism,likeRussiaandUkraine.ForexampleinRussia,
mortality initially fell rapidly for the first few years after the
collapse of the former Soviet Union but then began to rise after
the economic crisis in 1998.
26
Dramatic changes in Poland
InPoland,foodwasnolongersubsidisedafter1990;thiscaused
big changes in relative prices. As a consequence, the structure
of food consumed by Polish citizens changed substantially. For
example, between 1989 and 2008 annual butter consumption
decreased from 7 kg to 3.8 kg per head, and beef consumption
fell by 75%. At the same time availability and consumption of
fruits increased markedly.
5
On the other hand, shortly after the democratic transformation,
citizens’ purchasing power increased substantially, while
inequalities increased modestly. In Russia and Ukraine, in
contrast, such inequalities increased sharply in the 1990s.
27
The changes in Poland and its neighbours were revolutionary,
quite unlike those observed in any western European countries
at this time. The socioeconomic changes in Poland between
1991and2005reflectedsubstantialincreasesingrossdomestic
product per capita. This increased fourfold in Poland (from
$1998 (£1290, €1535) to $7963) but only twofold in the UK
(from $18 387 to $36 084, respectively).
27
Trends in population risk factors
The IMPACT model is a comprehensive tool that can quantify
changes in mortality as a function of improving treatments and
themajor“downstream”riskfactors:cholesterolconcentration,
bloodpressure,smoking,obesity,diabetes,andinactivity.Four
of these six major risk factors reflect dietary habits; these in
turn are powerfully patterned by “upstream” political and
socioeconomicfactors.Inouranalyses,weobservedapowerful
effect of changes in cholesterol concentration related to diet on
mortality from coronary heart disease in men and women. This
is consistent with the earlier hypothesis that favourable dietary
changes during transition were the main reason for the sharp
decline in cardiovascular mortality.
5 In contrast, statins made a
surprisingly small contribution to the overall reduction in
cholesterol concentration.
Between 1991 and 2005, systolic blood pressure decreased
substantially in women and young men but increased in men
aged over 55. This trend was consistently observed in three
different sets of contemporary local and national studies. It
generated over 1000 additional coronary deaths. It remains
unclear why such important and worrying sex differences
occurred in trends in blood pressure. More research is clearly
needed, particularly around possible sex and socioeconomic
differences in the intake of salt and other dietary factors.
Increasedphysicalactivityresultedinabout2500fewercoronary
deaths. The main benefits came from increases in leisuretime
physical activity in Poland and are now well documented.
28 29
There is no room for complacency, however, as recent data
suggest that over half of all adults are not sufficiently active.
Contributions of treatment
The number of evidence based treatments widely used in
cardiovascular medicine in Poland increased markedly,
mirroring other developed countries. These pharmacological
treatments and invasive procedures together explained barely
a third of the decrease in mortality (37%). This reflects a
dynamic development in clinical cardiology in Poland in the
late 20th century. Several new centres of invasive cardiology
were created during this period, with medical standards
comparable with those in Western countries. Moreover,
physicians could more easily participate in training focused on
modern evidence based pharmacotherapy. The modern
management of heart failure therefore made the single biggest
treatment contribution to the reduction in mortality from
coronary heart disease (12%). Despite huge financial support,
the impact of invasive cardiology on mortality was modest
(barely4%).Thisthereforesuggeststhatfuturestrategiesshould
prioritisepoliciestoreducethemajorcardiovascularriskfactors.
Interventions based on taxation and legislation should focus on
constant improvement in restriction of tobacco use and control
of junk food to deal with the growing epidemic of obesity and
diabetes. The worrying trends in blood pressure in men also
demand immediate attention.
Strengths and limitations of the study
Our study was a comprehensive quantitative analysis of the
causes of a sharp mortality fall in a country experiencing
transition from communism to democracy and a market
economy.TheIMPACTmodeliscomprehensiveandtakesinto
account all known important downstream risk factors and all
standard treatments. The model has been previously validated
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other analyses performed in the same settings.
Several limitations should also be noted. In Poland, data for the
initial analysis year (1991) were not complete and were less
representative than in subsequent years. We also assumed a
minimal lag time between changes in risk factors and changes
in mortality. This, however, seems reasonable.
4 30 28 The model
failed to explain 9% of the overall reduction in deaths from
coronary heart disease: residual confounding in many of the
riskfactoreffectestimatesislikely,and,furthermore,themodel
does not quantify all potential risk factors (such as
psychosocial).
31
Comparison with other studies
Thoughtheresultswithourmodelaregenerallyconsistentwith
other analyses conducted in western Europe, the US, and
elsewhere (fig 3⇓), interesting differences do exist. The
contribution from changes in population risk factors was even
bigger in Nordic countries, probably reflecting more effective
health policies at national and local levels.
32 In contrast, in the
UK the dietary changes were more modest, whereas large
reductionsinsmokingprevalencepowerfullyreducedmortality.
8
Conclusions and policy implications
In conclusion, coronary heart disease deaths in Poland
plummeted after 1989. Over half of the recent reduction in
mortality was associated with favourable changes in major
cardiovascular risk factors, while about a third was attributable
to modern treatments. These impressive results show the
powerful effect of moderate changes in population level risk
factors on mortality from coronary heart disease. The positive
trendsinriskfactorsprobablyreflectbeneficialchangesinfood
prices and accessibility after economic transformation. These
benefits were substantially greater than those from
improvements in healthcare systems and medical treatment.
These analyses have implications for strategies to fight future
epidemics of coronary heart disease. Effective legislation to
control smoking, dietary salt intake, and consumption of
saturatedfatandtransfatscouldbepowerful,rapidlybeneficial,
and cost saving. The “natural experiment” that occurred in
Polandnowrequiresfurthersupportfromevidencebasedpolicy
interventions.
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RESEARCHTables
Table 1| Estimated numbers of deaths from coronary heart disease prevented or postponed by medical and surgical treatments in Poland
in 2005*
Coronary heart disease deaths prevented or postponed
Eligible patients Patient groups and specific treatments % of total fall in mortality (range) Best estimate (range)†
5.1 (1.4-9.7) 1340 (370-2550) 52 180 Acute myocardial infarction
4.2 (2.1-7.1) 1110 (550-1850) 105 920 Unstable angina
4.9 (2.0-10.1) 1300 (520-2650) 213 970 Secondary prevention after myocardial infarction
2.4 (1.0-5.0) 630 (260-1310) 100 890 Secondary prevention after CABG/PTCA
2.7 (1.1-5.8) 710 (300-1510) 706 670 Chronic angina
5.6 (2.7-13.6) 1470 (700-3550) 18 330 Heart failure with hospital admission
6.2 (2.8-14.4) 1630 (730-3760) 122 680 Heart failure in the community
2.2 (−1.7-4.8) 580 (−440-1260) 8 488 520 Treatments for hypertension
3.4 (1.4-7.0) 880 (360-1830) 14 046 930 Statins for primary prevention lipid reduction
36.8 (12.8-77.5) 9640 (3350-20 270) — Total treatments
CABG/PTCA=coronary artery bypass graft/percutaneous transluminal coronary angioplasty.
*See technical appendix on bmj.com for detailed version of this table.
†Reported numbers rounded to nearest 10. Might not sum to total because of rounding.
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RESEARCHTable 2| Estimated coronary deaths prevented or postponed as a result of risk factor changes in men and women in Poland 1991-2005
Deaths prevented or postponed
Relative
risk
β
regression
coefficient
Change in risk factor
Absolute level of risk
factor
Population
risk factor
Percent of total
reduction (range) Best estimate* (range)
Relative
change (%)
Absolute
change 2005 1991
Prevalence of smoking (%):
15% (12%-18%) 2980 (2390-3580) 3.1 — −28.0 −15.7 40.1 55.8 Men
0% (0%-0%) −10 (−10-−10) 4.2 — −4.0 −3.0 25.1 28.1 Women
Systolic blood pressure (mm Hg) (antihypertensive treatment effects subtracted):
−8% (−6%-−12%) −1720 (−1250-−2380) — −0.034 −1.8 −2.7 137.4 140.1 Men
29% (19%-40%) 1690 (1100-2360) — −0.042 −3.4 −5.2 131.5 136.6 Women
Total cholesterol (mmol/L) (statin effects subtracted):
41% (29%-51%) 8390 (6010-10340) — −0.95 −8.6 −0.4 5.2 5.6 Men
33% (25%-38%) 1920 (1440-2200) — −0.91 −7.6 −0.4 5.2 5.6 Women
Physical inactivity (%):
10% (8%-12%) 2000 (1600-2400) 1.29 — −40.1 −25.9 38.7 64.6 Men
11% (9%-13%) 630 (510-760) 1.35 — −35.3 −24.3 44.5 68.8 Women
BMI:
−4% (−2%-−7%) −870 (−480-−1340) — 0.030 3.2 0.9 26.9 26.0 Men
−5% (−3%-−8%) −290 (−160-−450) — 0.027 3.2 0.9 26.6 25.7 Women
Prevalence of diabetes (%):
−1% (−1%-−1%) −190 (−130-−250) 2.47 — 12.7 0.4 3.3 2.9 Men
−8% (−5%-−11%) −460 (−310-−630) 3.40 — 28.5 0.9 4.2 3.3 Women
Total risk factors:
52% (40%-61%) 10 600 (8130-12340) — — — — — — Men
60% (44%-73%) 3 480 (2570-4230) — — — — — — Women
*Reported numbers rounded to nearest 10.
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RESEARCHFigures
Fig 1 Trends in mortality from heart disease in Poland, other former communist countries, and western European countries
in men aged ≤64 (source: WHO mortality database
3)
Fig 2 Observed reductions in coronary deaths in Poland across age and sex groups: comparison with model estimates
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:d8136 doi: 10.1136/bmj.d8136 (Published 25 January 2012) Page 9 of 10
RESEARCHFig 3 Percentage of reduction in deaths from coronary heart disease attributable to treatments and changes in risk factors
in our study and in other populations
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